Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.53 |
| ▸ | KIT | P10721 | 5/20 | 0.53 |
| ▸ | FLT1 | P17948 | 5/20 | 0.53 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681543 | 0.91 | KDR (0.49) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL4286386 | 0.89 | KDR (0.50) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL4280386 | 0.86 | KDR (0.52) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL13639016 | 0.86 | KDR (0.48) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL4285694 | 0.85 | KDR (0.51) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL3673895 | 0.82 | CDK8 (0.62) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL4360369 | 0.82 | BRAF (0.55) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL13636105 | 0.80 | KDR (0.47) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL3668920 | 0.80 | PDGFRB (0.53) | KDRPDGFRBKITFLT1AURKA | |
| SCHEMBL4280855 | 0.80 | MET (0.43) | KITALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | KDR 2311/4885PDGFRB 3323/4885KIT 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.